血浆外泌体lnc-SNAPC5-3:4在监测安洛替尼治疗晚期非小细胞肺癌疗效中的作用
核心信息
- 论文英文标题: The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer
- 期刊: J CANCER RES CLIN
- 发表年份: 2022
- DOI: 10.1007/s00432-022-04071-5
- PMID/PMCID: 35672525; PMC11800937
研究概览
The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical study to evaluate the efficacy of anlotinib in patients with advanced non-small cell lung cancer (NSCLC). Our results demonstrate the potential of plasma exosomal lnc-SNAPC5-3:4 as a biomarker for monitoring anlotinib efficacy.
核心发现
In the plasma exosomal RNA profiles of the 5 patients with advanced NSCLC during treatment with anlotinib, 7 miRNAs, 3 lncRNAs, and 83 mRNAs were significantly dysregulated.
The regulation trend was opposite when the treatment was effective and ineffective, showing dynamic changes.
Thus, it can be used as a potential biomarker for monitoring the efficacy of anlotinib.
研究设计
We enrolled 5 patients with advanced NSCLC, and 15 blood samples were collected before anlotinib treatment, when the treatment was effective, and when the treatment was ineffective.
The plasma exosomal RNA profiles were analyzed by whole-transcriptome sequencing at three different stages.
The expression of dysregulated exosomal RNAs in 43 additional patients was also verified by real-time quantitative PCR.
Echo Biotech 角色
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
关联平台: Exoomics®, Research Reagents & Tools
关联服务与能力: EV Isolation & Purification, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022. DOI: 10.1007/s00432-022-04071-5. PMID/PMCID: 35672525; PMC11800937.